In this issue of JAMA Internal Medicine, Perry and colleagues1 review the concordance of medicines safety advisories among drug regulatory authorities in Australia, Canada, the United Kingdom, and the United States during a 10-year period. Across 680 individual safety issues, the authors report significant differences in the frequency with which individual regulatory authorities issued safety advisories for drugs approved in their respective jurisdictions, ranging from 29.6% (Australia) to 52.4% (United Kingdom). The frequency with which only 1 of the 4 regulatory authorities issued a safety advisory for an individual issue ranged from 11.1% (Australia) to 20.7% (United Kingdom).